What's in Universitas Sebelas Maret's pipeline?

Universitas Sebelas Maret has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Universitas Sebelas Maret's portfolio?

Top competitors by shared drug class: Changhua Christian Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universitas-sebelas-maret.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Universitas Sebelas Maret — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Universitas Sebelas Maret pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Hyperbaric Lidocaine 5%	Hyperbaric Lidocaine 5%	marketed
Oral lumbrokinase DLBS1033	Oral lumbrokinase DLBS1033	marketed	Fibrinolytic enzyme	Fibrin; plasminogen activation pathway	Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Changhua Christian Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universitas Sebelas Maret:

Cite this brief

Drug Landscape (2026). Universitas Sebelas Maret — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universitas-sebelas-maret. Accessed 2026-05-17.